FDC Limited's Recurring Timolol Maleate Recall Signals Persistent Container Defects, Heightening US Supply Chain Risk
FDC Limited has initiated a Class II recall of 155,232 bottles of Timolol Maleate Ophthalmic Solution USP, 0.5%, due to defective containers. This marks the third such recall for the Aurangabad, India-based manufacturer in 2024, distributed by Rising Pharma Holdings, Inc. This recurring issue underscores significant quality control deficiencies, posing substantial supply chain and regulatory risks for procurement and regulatory affairs teams.
FDC Limited Initiates Class II Recall for Defective Timolol Maleate Ophthalmic Solution
FDC Limited, a pharmaceutical manufacturer based in Aurangabad, Maharashtra, India, has voluntarily initiated a Class II recall (D-0035-2025) for 155,232 bottles of its Timolol Maleate Ophthalmic Solution USP, 0.5%. This action, commenced on October 29, 2024, addresses a critical product defect: the container's cap spike was found lodged in the nozzle, rendering the solution inaccessible to patients. The affected product is identified by NDC 64980-514-05, specifically Lot #: 083L051, with an expiration date of November 2025. This recall directly impacts the US market, as the product was distributed to a single US distributor, Rising Pharma Holdings, Inc. in New Jersey. For procurement directors, this event necessitates an immediate review of existing stock and orders for Timolol Maleate sourced from FDC Limited, particularly for the specified lot. The inability to dispense medication directly affects patient treatment continuity and can lead to significant reputational damage for distributors and pharmacies. Regulatory affairs heads must note the Class II classification, indicating that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This incident highlights the imperative for robust incoming quality control checks on packaging components and finished goods from overseas manufacturers.
Manufacturing Origin and US Distribution Chain for Timolol Maleate
The recalled Timolol Maleate Ophthalmic Solution USP, 0.5% originates from FDC Limited's manufacturing facility located in Waluj, Aurangabad, Maharashtra State, India. This facility serves as a key supplier for generic ophthalmic solutions entering the US market. The product, a human prescription drug, is an essential medication for treating glaucoma and ocular hypertension. Post-manufacturing, the affected lot was distributed to one US distributor, Rising Pharma Holdings, Inc., situated in New Jersey. This concentrated distribution model means that the impact of this recall is channeled through a single point of contact within the US supply chain. For supply chain VPs, this scenario underscores the inherent risks associated with relying on a limited number of manufacturing sites and distribution partners, particularly for critical pharmaceutical products. Any disruption at the manufacturing origin, such as quality control failures, can propagate rapidly through a narrow distribution channel, leading to immediate and widespread market shortages. Business development executives should evaluate the resilience of their sourcing strategies for essential generics, considering the geographic concentration of manufacturing and the potential for single points of failure.
Market Impact and Distributor Implications for Rising Pharma Holdings
The recall of 155,232 bottles of Timolol Maleate Ophthalmic Solution USP, 0.5% directly impacts Rising Pharma Holdings, Inc., the sole US distributor for this specific FDC Limited product. This quantity represents a substantial volume of product that must be removed from the market, leading to immediate revenue loss and logistical complexities for the distributor. Procurement directors at Rising Pharma Holdings, Inc. and its downstream customers must now manage the return and destruction of affected inventory, while simultaneously scrambling to secure alternative supplies to meet ongoing patient demand for Timolol Maleate. The disruption extends beyond the immediate financial cost, affecting pharmacy relationships and patient trust. For business development executives, such events can strain partnerships with manufacturers and expose vulnerabilities in product portfolios reliant on single-source generics. The incident necessitates a comprehensive assessment of the contractual obligations and liabilities between FDC Limited and Rising Pharma Holdings, Inc., particularly concerning quality failures and recall costs. Furthermore, the event may prompt a re-evaluation of supplier qualification processes, emphasizing not only manufacturing quality but also packaging integrity to prevent similar dispensing issues.
Mitigating Supply Chain Disruptions: Alternative Sourcing Considerations for Timolol Maleate
Given the recurring nature of container defects from FDC Limited, procurement teams must proactively explore alternative sourcing options for Timolol Maleate Ophthalmic Solution USP, 0.5%. While specific alternative suppliers are not identified in our current intelligence, the market for generic ophthalmic solutions typically includes multiple manufacturers globally. Procurement directors should immediately initiate a comprehensive supplier qualification process, focusing on manufacturers with robust quality management systems and a proven track record of packaging integrity. This process should include rigorous audits of manufacturing facilities, packaging lines, and quality control protocols to ensure compliance with FDA standards. Prioritizing geographically diverse suppliers can also reduce reliance on a single region, mitigating risks associated with localized regulatory actions or geopolitical events. The qualification timeline for a new pharmaceutical supplier can range from 12 to 24 months, depending on the complexity of the product and the regulatory requirements. Therefore, early engagement in identifying and vetting potential alternatives is critical to prevent long-term supply disruptions and maintain market access for this essential ophthalmic drug.
FDC Limited's Recurring Quality Control Challenges: A Pattern of Container Defects
This latest recall of Timolol Maleate Ophthalmic Solution USP, 0.5% is not an isolated incident for FDC Limited. Our intelligence indicates a concerning pattern of recurring quality control issues related to container defects for the same product. FDC Limited has faced similar voluntary Class II recalls for Timolol Maleate Ophthalmic Solution earlier in 2024, with events reported on May 15, 2024, and August 28, 2024. This history strongly suggests systemic deficiencies in the company's manufacturing processes, specifically concerning packaging component design, material quality, or assembly. For regulatory affairs heads, this recurring problem elevates the risk profile of FDC Limited's Aurangabad facility. Repeated quality failures, particularly those impacting product usability, typically trigger heightened scrutiny from the FDA. This pattern could lead to more severe regulatory actions, including official Warning Letters detailing specific manufacturing practice violations, or even the imposition of an Import Alert, which would effectively block all products from the affected facility from entering the US market. Procurement directors must recognize that a manufacturer with a history of recurring recalls presents a higher inherent supply risk, necessitating more stringent oversight and potentially a re-evaluation of the supplier relationship.
Ongoing Recall Status and Future Compliance Outlook for FDC Limited
The Class II recall for FDC Limited's Timolol Maleate Ophthalmic Solution USP, 0.5% is currently classified as 'Ongoing,' indicating that the firm is actively working to remove the affected product from the market and address the root cause of the defect. As part of its remediation efforts, FDC Limited will be required to implement comprehensive Corrective and Preventive Actions (CAPAs) to address the defective container issue. Given the history of similar recalls in 2024, the FDA is likely to monitor FDC Limited's remediation progress closely. Failure to effectively resolve these recurring quality control problems could lead to an escalation of regulatory oversight. This could manifest as an official FDA Warning Letter, which publicly identifies significant deviations from Good Manufacturing Practices (GMPs), or, in more severe cases, an Import Alert. An Import Alert would prevent all drug products from FDC Limited's Aurangabad, Maharashtra facility from entering the United States until the company demonstrates full compliance. Supply chain VPs and business development executives should anticipate potential disruptions to other FDC Limited products if such an alert is issued. Proactive engagement with FDC Limited to understand their CAPA plan and timeline is essential for mitigating future supply chain risks and ensuring continuous market access for their products.